Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress
May 21, 2020 07:00 ET
|
Imara, Inc.
BOSTON, May 21, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Reports First Quarter 2020 Financial Results and Business Highlights
May 07, 2020 07:00 ET
|
Imara, Inc.
Strengthened Board of Directors and expanded leadership team with appointment of General Counsel Continued progress toward initiation of Phase 2b clinical trials of IMR-687 in sickle cell disease and...
Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results
May 06, 2020 16:05 ET
|
Morphic Therapeutic
Data presented at ECCO Congress support MORF-057 in IBD; IND on track for mid-year Recent executive appointments of Peter Linde, M.D., as CMO and Marc Schegerin, M.D., as CFO and COO ...
Imara Announces Appointment of Stephen M. Migausky as General Counsel
May 04, 2020 07:00 ET
|
Imara, Inc.
BOSTON, May 04, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference
April 29, 2020 16:15 ET
|
Morphic Therapeutic
WALTHAM, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.
April 23, 2020 07:00 ET
|
Imara, Inc.
Industry leader with global clinical development expertise to help guide Imara’s clinical advancement Imara also announces departure of Chief Medical Officer, Willem Scheele BOSTON, April 23, 2020 ...
Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer
April 07, 2020 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer
March 17, 2020 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
IMARA Announces Pricing of Initial Public Offering
March 11, 2020 21:57 ET
|
Imara, Inc.
BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019
February 27, 2020 16:05 ET
|
Morphic Therapeutic
WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...